RAMAT GAN, Israel, March  04, 2026  (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) (&#34;Can-Fite&#34; or the &#34;Company&#34;), a biotechnology company advancing a pipeline of proprietary small-molecule drugs

CANF

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

Can-Fite Secures $4 Million from Warrant Exercise for R&D

Can-Fite BioPharma Ltd. (AMEX: CANF) shares are up on Wednesday following the company's announcement...

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>RAMAT GAN, Israel, March  04, 2026  (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) (&amp;#34;Can-Fite&amp;#34; or the &amp;#34;Company&amp;#34;), a biotechnology company advancing a pipeline of proprietary small-molecule drugs</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Can-Fite BioPharma is set to raise approximately $4 million through the immediate exercise of existing warrants, significantly impacting its funding for research and development activities. The new warrants to be issued will further strengthen the company’s capital position, expected to close by March 5, 2026.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Can-Fite offers immediate exercise of warrants for $4 million funding.</li><li>Warrants exercise proceeds will support R&amp;D and clinical trials.</li><li>New warrants issued at $5.00 per ADS, exercisable for 24 months.</li><li>H.C. Wainwright &amp; Co. acts as the placement agent.</li><li>Closing expected by March 5, 2026, pending customary conditions.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>H.C. Wainwright &amp; Co. (N/A)</strong>: Acting as the exclusive placement agent for Can-Fite&#039;s warrant offering.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This event falls under Corporate Developments as it pertains to Can-Fite’s funding strategies, directly affecting its operational capabilities and future growth potential in the biotech sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The exercise of warrants provides $4 million in immediate liquidity for Can-Fite.</li><li>New warrants enhance future financing options, possibly increasing investor interest.</li><li>Completion of the offering is expected soon, impacting share liquidity.</li><li>Use of proceeds targeted for R&amp;D could drive long-term valuation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Gross proceeds expected from warrant exercise: $4 million.</li><li>New warrants allow purchase of up to 1,591,738 ADSs at $5.00 each.</li><li>Previous warrants had an exercise price of $9.34.</li><li>The offering is set to close around March 5, 2026.</li><li>H.C. Wainwright &amp; Co. is the exclusive placement agent.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Can-Fite may see positive price movement from funding news in the near term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>RAMAT GAN, Israel, March  04, 2026  (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CANF">CANF</a>) (TASE: CANF) ("Can-Fite" or the "Company"), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 795,869 American Depositary Shares (ADSs), having an exercise price of $9.34 per ADS, issued by Can-Fite in July 2025, at a reduced exercise price of $5.00 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-1 (File No. 333-288890). The closing of the offering is expected to occur on or about March 5, 2026, subject to satisfaction of customary closing conditions.</p>  <p>H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</p>  <p>In consideration for the immediate exercise of the warrants for cash, Can-Fite will issue new unregistered warrants to purchase up to 1,591,738 ADSs. The new warrants will have an exercise price of $5.00 per ADS, will be immediately exercisable until the twenty-four month anniversary of the effective date of the Resale Registration Statement.</p>  <p>The gross proceeds to Can-Fite from the exercise of the warrants are expected to be approximately $4.0 million, prior to deducting placement agent fees and offering expenses. The Company intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.</p>  <p>The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the &#34;1933 Act&#34;), and, along with the ADSs issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (&#34;SEC&#34;) or an applicable exemption from such registration requirements. Can-Fite has agreed to file a registration statement with the SEC covering the resale of the shares of ADSs issuable upon exercise of the new warrants (the "Resale Registration Statement").</p>  <p>This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>  <p><b>About Can-Fite BioPharma Ltd.</b></p>  <p>Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CANF">CANF</a>) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company&#39;s lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite&#39;s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company&#39;s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: <a href="https://www.globenewswire.com/Tracker?data=W_pgCBWaUUxPq0X2ZF7AaDyyPgXCMetjwK8s_AlwtZqvp54HnqIV7ycv1Exft95V4z6v0VEu8aPBF_xfFofJgXWAPKAOaekkgBZ8te0Ho4g=" rel="nofollow" target="_blank">https://www.canfite.com/</a>.  </p>  <p><b>Forward-Looking Statements</b></p>  <p>This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.</p>  <p><b>Contact</b></p>  <p>Can-Fite BioPharma<br></br>Motti Farbstein<br></br><a href="https://www.globenewswire.com/Tracker?data=zadg3U-QMXj0EHCfnRMvwdNeup-ilLXvMJuGyjzJQ85XBvxCVRdfaklWYQR7pe3JH-2oftOLsxFYMBsAnhzOYTE-HwezCDP0GqmFKUbMqdE=" rel="nofollow" target="_blank">info@canfite.com</a> <br></br>+972-3-9241114</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NTc2OCM3NDY3NDcwIzUwMDA2NjI5Mw=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NDJjNGEyNzQtY2M1OS00ODY1LTk5YjEtODgyYWM5Njk0NjIyLTUwMDA2NjI5My0yMDI2LTAzLTA0LWVu/tiny/Can-Fite-BioPharma-Ltd-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ca5e71b0-5c40-4d54-96ce-7ce704201c96"><img src="https://ml.globenewswire.com/media/ca5e71b0-5c40-4d54-96ce-7ce704201c96/small/can-fite-biopharma-logo-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Can-Fite BioPharma is set to raise approximately $4 million through the immediate exercise of existing warrants, significantly impacting its funding for research and development activities. The new warrants to be issued will further strengthen the company’s capital position, expected to close by March 5, 2026.

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News